Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XMT 1522

Next Previous
Search
Drug Profile

XMT 1522

Alternative Names: TAK 522; XMT1522

Latest Information Update: 01 Mar 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adimab; Mersana Therapeutics
  • Developer Mersana Therapeutics; Takeda
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Gastric cancer; HER2 positive breast cancer; Non-small cell lung cancer

Most Recent Events

  • 01 Mar 2021 700267360: CTP push-Updated KDM for trial completion and added HE for the same
  • 28 Jan 2019 Mersana Therapeutics completes a phase I trial in HER2-positive-breast cancer, Gastric cancer and Non-small Cell Lung Cancer in the USA (NCT02952729)
  • 04 Jan 2019 Discontinued - Phase-I for Gastric cancer (Late-stage disease) in USA (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top